VIVUS Reports Second Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/25/2026
- S&P 500 ends marginally lower as investors focus on US-Iran war
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oil gains on little sign of progress in US-Iran talks
- S&P 500 history shows strong gains across Fed hiking cycles: BCA
- JPMorgan upgrades CoreWeave on stronger compute pricing
- Bloom Energy falls as Oracle invokes force majeure on AI project
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oracle Sends Force Majeure Notice Over New Mexico Data Center - Bloomberg
- Akamai signs $11.6B deal with Anthropic, up to $20B potential
- US and Iran discuss phased deal to reopen Hormuz and end US blockade, sources say
Vivus (VVUS) PT Cut to $4 at RBC Capital on Disappointing Results, Deep Cost Cuts; Keeps 'Outperform'
July 31, 2015 8:37 AM EDTRBC Capital analyst Simos Simeonidis lowered his price target on Vivus (NASDAQ: VVUS) to $4.00 (from $6.00) but maintained his Outperform rating following Q2 results.
Simeonidis notes, "With Qsymia 2Q15 revenue at just $14M, Vivus is trying to preserve cash. It has announced further cost cutting,... More
VIVUS (VVUS) Tops Q2 EPS by 5c
July 30, 2015 4:01 PM EDTVIVUS (NASDAQ: VVUS) reported Q2 EPS of ($0.19), $0.05 better than the analyst estimate of ($0.24). Revenue for the quarter came in at $23 million versus the consensus estimate of $18.76 million.
"The U.S. market for branded anti-obesity pharmacotherapeutics has developed at a substantially lower rate than expected, held in check by a number of factors," said Seth H. Z. Fischer, CEO. "As stated previously, we have watched this trend closely... More
